247 320
[7]
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.[8]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treat- ment with curative intent. Eur Urol 2017;71:618–29.[9]
Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000;47:609–15.[10]
Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792–7.
[11]
Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of Cali- fornia, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938–42.
[12]
Carroll PR, Parsons JK, Andriole G, et al. NCCN Guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw 2016;14:509–19.
[13]
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74.
[14]
Kryvenko ON, Carter HB, Trock BJ, Epstein JI. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014;83:869–74.
[15]
Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 Interna- tional Society of Urological Pathology (ISUP) Consensus Confer- ence on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228–42.[16]
Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244–52.
[17]
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346–52.
[18]
Nakabayashi M, Hayes J, Taplin M-E, et al. Clinical predictors of survival in men with castration-resistant prostate cancer: evi- dence that Gleason score 6 cancer can evolve to lethal disease. Cancer 2013;119:2990–8.
[19]
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753–60.[20]
Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016;69:428–35.
[21]
Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classifica- tion of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016.
[22]
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 2016;70:106–19.
[23]
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.[24]
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42.[25]
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–24.
[26]
Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425–37.
[27]
Dinh KT, Mahal BA, Ziehr DR, et al. Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol 2015;194:343–9.
[28]
Song SH, Pak S, Park S, et al. Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D’Amico criteria: role of multiparametric magnetic resonance imaging. J Urol 2014;192:402–8.
[29]
Weiner AB, Patel SG, Eggener SE. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol 2015;33:164.e11–7.
[30]
Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012;187:1620–5.
[31]
Imnadze M, Sjoberg DD, Vickers AJ. Adverse pathologic features at radical prostatectomy: effect of preoperative risk on oncologic outcomes. Eur Urol 2016;69:143–8.
[32]
Beauval J-B, Ploussard G, Soulie´ M, et al. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 2012;80:656–60.
[33]
Carlsson S, Ja¨derling F, Wallerstedt A, et al. Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAP- PRO trial. BJU Int 2016;118:205–12.
[34]
Auffenberg GB, Linsell S, Dhir A, et al. Comparison of pathological outcomes for men with low risk prostate cancer from diverse practice settings: similar results from immediate prostatectomy or initial surveillance with delayed prostatectomy. J Urol 2016;196:1415–21.
[35]
Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll PR. Immediate versus delayed radical prostatectomy: updated out- comes following active surveillance of prostate cancer. Eur Urol 2015;68:458–63.
[36]
Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and Longer- term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015;33:3379–85.
[37]
Godtman RA, Holmberg E, Khatami A, Pihl C-G, Stranne J, Hugos- son J. Long-term results of active surveillance in the Go¨teborg Randomized, Population-based Prostate Cancer Screening Trial. Eur Urol 2016;70:760–6.
[38]
Bokhorst LP, Valdagni R, Rannikko A, et al. A decade of active surveillance in the PRIAS Study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 2016;70:954–60.
[39]
Bokhorst LP, Alberts AR, Rannikko A, et al. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 2015;68:814–21.
[40]
Welty CJ, Cowan JE, Nguyen H, et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 2015;193:807–11.
[41] Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M.
Prostate cancer EAU-guidelines. 2015
https://uroweb.org/ guideline/prostate-cancer/#5[42]
Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009;6:205–15.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 3 8 – 2 4 9
247